Werkgroep Cardiologische centra Nederland English

TECOS (Afgerond)

A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (TECOS)
Middel
Sitagliptin
Populatie
ASCVD
Fase
III
Jaar aanvang
2008
Meer informatie
Clinicaltrials.gov

Publicaties: TECOS

  • Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS TrialCirculation - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOSDiabetes Obes Metab - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSDiabetes Care - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol. - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Discussant review: impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine - TECOS - ASCVD

Publicaties per WCN-studie

Publicaties WCN-studies per WCN-lid